© 2023 MJH Life Sciences and CGTLive™. All rights reserved.
© 2023 MJH Life Sciences™ and CGTLive™. All rights reserved.
January 30, 2023
There were no deaths or safety signals identified by the DSMB for the 3 treated patients in cohort 1.
January 29, 2023
No adverse events related to the infusions of stromal cells were reported.
January 27, 2023
Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.
No dose-limiting toxicities were observed at 28 days of follow-up.
January 26, 2023
Nearly half of participants were able to engage in normal physical activity without angina at 6 months post-treatment.
Patients continued to show statistically significant upper limb performance improvements.
January 25, 2023
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The dosing of the first patient took place in December 2022 and no adverse events related to the therapy have been reported.
January 24, 2023
No patients treated with Tevogen Bio’s TVGN 489 showed progression of their COVID-19 infections.
January 23, 2023
REGENXBIO has also initiated recruitment for AFFINITY BEYOND, an observational study assessing the prevalence of AAV8 antibodies in male patients with DMD.